Trump Executive Order On Drug Pricing Is A Mixed Bag For Pharma

Fast Followers May Win Quicker Path To Approval

 
• By Mandy Jackson
  
Small molecule developers could benefit from Trump's executive order but specifics are unclear (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Market Access